International Medical Products Anti-CounterfeitingTaskforce.

Slides:



Advertisements
Similar presentations
PRECURSOR CHEMICALS.
Advertisements

الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization.
U.S. Government Coordinated Approach to IPR Protection and Enforcement 4 th Global Congress on Combating Counterfeiting & Piracy February 3-5, 2008 Wayne.
Efforts of Pakistan to Curb Electronic Crimes and Combat Cyber Terrorism Syed Mohammed Anwer Director Legal Ministry of Information Technology Government.
Combating counterfeit medicines in Vietnam. Issues Definitions of counterfeit medicines and concerned legal documents National coordination Number of.
Country Presentation Myanmar
FIRST ASEAN – CHINA CONFERENCE ON COMBATING COUNTERFEIT MEDICINAL PRODUCTS JAKARTA, NOVEMBER 07 COUNTRY PRESENTATION CAMBODIA Presented by Dr. Chhieng.
Copyright of the Health Sciences Authority 2007 ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta, November 2007 Singapore.
Combating Counterfeit Drugs in China Chen Xu Ph.D. Director of Division of Drug Supervision and Inspection Department of Drug Market.
IMPACT Principles and Elements for National Legislation Presented by: Chair, Working Group on Regulatory Implementation, on behalf of Chair, Working Group.
International Medical Products Anti-CounterfeitingTaskforce INSPECTOR OF DRUGS NATIONAL DRUG AUTHORITY- UGANDA.
Counterfeit and Substandard medicine in Laos Report country.
COMBATING COUNTERFEIT DRUGS IN INDONESIA
Anti- Piracy Unit (APU) REPUBLIC OF MAURITIUS 1. MAURITIUS 2.
International Medical Products Anti-CounterfeitingTaskforce.
1 Counterfeit Medicines & Japan 1st ASEAN-CHINA Conference on combating Counterfeit Medical Product (Jakarta) November 2007 Kazuko KIMURA Prof. Ph.D.
IMPACT REGIONAL CONFERENCE ON COMBATING COUNTERFEIT MEDICAL PRODUCT: 9-10 NOVEMBER 2009: KEMPTON PARK,SOUTH AFRICA: BY DETECTIVE INSPECTOR NAMIBIA.
IMPACT Regional Conference on Combacting Counterfeit Medical Products 9-10 November 2009 Kempton Park – South Africa Mozambique Experience.
International Medical Products Anti-CounterfeitingTaskforce.
WHO Good Distribution Practices for Pharmaceutical Products
International Medical Products Anti-CounterfeitingTaskforce.
First ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta November 2007 CHOO CHEOK HANG DEPARTMENT OF PHARMACEUTICAL SERVICES.
A WHO initiative to combat counterfeit medical products Dr V. Reggi World Health Organization.
Article 54 CISA and the ECJ/CGEU case law
JAMAICA PEGASUS 22 ND -24 TH MARCH 2011 ANTIGUA AND BARBUDA Davidson Whyte Assistant Commissioner of Police.
ISSUES AND CONCERNS IN THE UGANDA COUNTERFEIT GOODS BILL MULUMBA, MOSES.
Working world wide against HIV for the health and human rights of men who have sex with men Working world wide against HIV for the health and human rights.
Health & Safety at Work Etc. Act 1974
World Health Organization
BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh,
STATEMENT BY THE MINISTER OF STATE FOR ETHICS AND INTEGRITY, OFFICE OF THE PRESIDENT UGANDA AT THE 4 TH IAACA ANNUAL SEMINAR DALIAN, CHINA 25 TH TO 28.
The Competent Supervisor
Bid Rigging Legal Framework in Zambia Natalie Nakazwe Research Analyst.
Consumer Safety and Drug Regulations
MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.
Canada’s Drug Strategy. 2 Purpose Provide an overview of Canada’s renewed National Drug Strategy  Historical context  Impetus for change  Renewed National.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
National Environmental Laws Amendment Bill [B ] Clause by clause analysis – Portfolio Committee on Environmental Affairs and Tourism: 10 October.
Customer Service Enforcement After AB 2987 John Risk Communications Support Group, Inc. (c) 2006 John Risk Communications Support Group, Inc. (c) 2006.
Make/Revise a Law Summative. LEARNING GOAL (Cause and Consequence) You will identify and explain the relationship between societal problems and the creation.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
Cal-OSHA and Labor Code Understanding the Law And Its Consequences
AUDIT, RECOVERY PROCEDURES & PENALTIES UNDER SALES TAX ACT, 1990 AND FEDERAL EXCISE ACT 2005 BY MUNIR QURESHI CHIEF COLLECTOR OF CUSTOMS (SOUTH)
Zambia’s Porous Borders & the Influx of Medicines.
CIVILIAN SECRETARIAT FOR POLICE. PRESENTATION TO THE SELECT COMMITTEE ON SECURITY AND CONSTITUTIONAL DEVELOPMENT OF THE NCOP 11 SEPTEMBER 2013 CRIMINAL.
EQUAL REMUNERATATION ACT INTRODUCTION The principle of equal work to men and women worker has been gaining increasing acceptance all over the world.
1999 Health Insurance Scheme Decree FEMI JOHNSON & COMPANY LIMITED Incorporated Insurance Brokers Rc7415 Member, Nigerian Corporation of Registered Insurance.
1 Patel Harsh C. Mech -B Roll No Environment protection act,1986:  Act to provide for the protection and improvement of environment.  It shall.
DISCOVERY HEALTH COMMENTS ON THE MEDICINES AND RELATED SUBSTANCES BILL August 2008.
IPASA presentation to Portfolio Committee on Health 31 October 2014 Abeda Williams.
CHAPTER 14 – OCCUPATIONAL SAFETY AND HEALTH
Medicines and Related Substances Amendment Bill 2008 Pharmaceutical Task Group: Industry Marketing Code Steering Committee Presented by: Maureen Kirkman.
Minimum Wages Act 1948.
INTRODUCTION AND OBJECTIVES LEGAL ASPECTS AND SOCIO-ECONOMIC IMPLICATIONS REGARDING DRUG COUNTERFEITING CIOBANU CONSTANTIN, CORCIOVĂ ANDREIA Faculty of.
ARTICLE X Appropriations, Management of Funds and Annual Report Section 87. Appropriations. The amount necessary for the operation of the Board and the.
Presentation to the 6 th Annual African Dialogue on Consumer Protection Conference, September 2014 The views and opinions expressed herein are those.
IPR Enforcement in the United Kingdom Kenny Wright Danish Patent and Trademark Office.
The criminalization of hacking tools as a reasonable measure of protection regarding attacks against information systems and computer data By Chatziioannou.
MEDICINES CONTROL AUTHORITY OF ZIMBABWE
Sophie Honohan Barrister-at-Law, Accredited Mediator 21 st April, 2016 Health Identifiers Act Conference.
Prof. Dr. Dr. Moni Wekesa LL.B Hons, LL.M, PhD Law, Dip (KSL), B.ED Sc, M.Sc, PhD Sports Medicine.
The Tragedy of Ignorance, Contradictions and Stigmatization
Strengthen Enforcement of Labour Legislation and Regulations, Beyond Labour Inspection Presented by: Althea Albury Senior Deputy Director of Labour Ministry.
Public Information Centre
Comparing Numbers.
a WHO initiative to combat counterfeit medicines
OHSC 2018 CONSULTATIVE WORKSHOPS CERTIFICATION AND ENFORCEMENT
PRESENTER: MR. KOZHI KATAKA, LLB
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
Presentation transcript:

International Medical Products Anti-CounterfeitingTaskforce

Map of Our Country

A counterfeit pharmaceutical product can be defined as a pharmaceutical product which is deliberately and fraudulently mislabeled with respect to identity and/or source. According to WHO. We have no specific legislation that has attempted to give a definition of counterfeit medical products. Definition of counterfeit medical product used in our country

There is no National Legislation specific on counterfeit medicinal products in Zambia. However, the Pharmaceutical Act No 14 of 2004 Part IV Section 33. (1) provides that – A person shall not manufacture, import, export, distribute or sell substandard, counterfeit or adulterated medicines or allied substances. The penal code sections 363 and 376 give provisions on counterfeit coins and counterfeiting trademark respectively Our National Legislation

Pharmaceutical Act No 14 of 2004 Part IV 33. (2) provides for the penalties as follows: A person who contravenes subsection (1) commits an offence and shall be liable upon conviction, to a fine of not less than three hundred thousand penalty units but not exceeding five hundred thousand penalty units or to imprisonment for a term of not less than five years but not exceeding ten years, or both. 1 penalty unit is = K180 Thus K 54 to 90 Million (12 – 20 thousand US dollars) Penalties

The MDTF is a grouping of ZP, PRA, DEC and MOH but does not address IPR protection It deals with the actual chemical composition $ quality aspects of the drugs and Help in the enforcement of the PRA Act Operation Zambezi (12 – 16 october 2009 in Lusaka) highlighted serious limitations of the MDTF. Efforts have since been made towards the formation of a National Steering Committee targeted at counterfeit medical products. National coordination

Number of cases SuspectedConfirmedImported / DomesticVital Medicines Nil Nil 2006Nil 2005Nil How where these cases detected? number of cases Patients complaints 01 Health professionals reportsNil Enforcement/investigation workNil Routine checks02 Reported by affected manufacturer/importer01 OtherNil

Only two (2) cases prosected Two companies involved were successfully prosecuted and convicted (fined) in One is still pending. Number of prosecutions, convictions & pending cases

Establish a National Steering Committee on counterfeit medicinal products Fully equip and expand the National Pharmacovigilance Unit at PRA so as to effectively handle counterfeit medicinal products. Establish a fully fledged National Drug Quality Control Laboratory Increase capacity and staffing levels for inspectors Our proposals for action